Substituted benzo[d]oxazol-2(3H)-one derivatives with preference for the σ1 binding site

European Journal of Medicinal Chemistry

Volumn 44, Issue 1, 2009, Pages 124-130

  Zampieri, Daniele ^a   Grazia Mamolo, Maria ^a   Laurini, Erik ^a   Zanette, Caterina ^a   Florio, Chiara ^a   Collina, Simona ^b   Rossi, Daniela ^b   Azzolina, Ornella ^b   Vio, Luciano ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Receptors; Benzo d oxazol 2(3H) one derivatives; Radioligand binding assays

Indexed keywords

3 [[1 (4 CHLOROBENZYL)PIPERIDIN 4 YL]METHYL]BENZO[D]OXAZOL 2(3H) ONE; BENZO[D]OXAZOL 2(3H) ONE DERIVATIVE; OXAZOLONE; SIGMA OPIATE RECEPTOR; SIGMA1 RECEPTOR; SIGMA2 RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BINDING SITE; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; NONHUMAN; RAT; RECEPTOR AFFINITY; STRUCTURE ANALYSIS;

ANIMALS; BENZOXAZOLES; BINDING SITES; BINDING, COMPETITIVE; LIGANDS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SIGMA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 57949107456     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2008.03.011     Document Type: Article

References (37)

1. Martin W.R., Eades C.E., Thompson J.A., and Huppler R.E. J. Pharmacol. Exp. Ther. 197 (1976) 517-532
2. Hellewell S.B., and Bowen W.D. Brain Res. 527 (1990) 235-236
3. Itzhak Y., and Stein I. Brain Res. 566 (1991) 166-172
4. Quirion R., Bowen W.D., Itzhak Y., Junien J.L., Mustacchio J.M., Rothman R.B., Su T.P., Tam S.W., and Taylor D.P. Trends Pharmacol. Sci. 13 (1992) 85-86
5. Bowen W.D. Pharm. Acta Helv. 74 (2000) 211-218
6. Hanner M., Moebius F.F., Flandorfer A., Knaus H.G., Striessnig J., Kempner E., and Glossmann H. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 8072-8077
7. Kekuda R., Prasad P.D., Fei Y., Leibach F.H., and Ganapathy V. Biochem. Biophys. Res. Commun. 229 (1996) 553-558
8. Walker J.M., Bowen W.D., Walker F.O., Matsumoto R.R., De Costa B., and Rice K.C. Pharmacol. Rev. 42 (1990) 355-402
9. Hellewell S.B., Bruce A., Feinstein G., Orringer J., Williams W., and Bowen W.D. Eur. J. Pharmacol., Mol. Pharmacol. Sec. 268 (1994) 9-18
10. Glennon R.A., Ablordeppey S.Y., Ismaiel A.M., El-Ashmawy M.B., Fischer J.B., and Howie B.K. J. Med. Chem. 37 (1994) 1214-1219
11. Ablordeppey S.Y., Fischer J.B., Law H., and Glennon R.A. Bioorg. Med. Chem. 10 (2002) 2759-2765
12. Glennon R.A. Minirew. Med. Chem. 5 (2005) 927-940
13. Gund T.M., Floyd J., and Jung D. J. Mol. Graphics Model. 22 (2004) 221-230
14. Wyrick S.D., and Booth R.C. Drugs Future 20 (1995) 1033-1044
15. Debonnel G., and De Montigny C. Life Sci. 58 (1996) 721-734
16. Monnet F.P., Debonnel G., and De Montigny C. J. Pharmacol. Exp. Ther. 261 (1992) 123-130
17. Maurice T., and Lockhart B.P. Prog. NeuroPsychopharmacol. Biol. Psych. 21 (1997) 69-102
18. King M., Pan Y.X., Mei J., Chang A., Xu J., and Pasternak G.W. Eur. J. Pharmacol. 331 (1997) R5-R6
19. McCracken K.A., Bowen W.D., Walker F.O., De Costa B., and Matsumoto R.R. Eur. J. Pharmacol. 370 (1999) 225-232
20. Modell S., Nober D., and Holzbach R. Pharmacopsychiatry 29 (1996) 63
21. Huber M.T., Gotthardt U., Schreiber W., and Krieg J.C. Pharmacopsychiatry 32 (1999) 68
22. Bastianetto S., Perrault G., and Ranger D.J. Neuropharmacology 34 (1995) 107-114
23. Jeanjean A.P., Laterre E.C., and Maloteaux J.M. Biol. Psych. 41 (1997) 1010-1019
24. Vilner B.J., John C.S., and Bowen W.D. Cancer Res. 55 (1995) 408-413
25. Crawford K.W., and Bowen W.D. Cancer Res. 62 (2002) 313-322
26. Vilner B.J., and Bowen W.D. J. Pharmacol. Exp. 292 (2000) 900-911
27. Crawford K.W., Coop K.W., and Bowen W.D. Eur. J. Pharmacol. 443 (2002) 207-209
28. Caveliers V., Everaert H., Lahoutte T., Dierickx L.O., John C.S., and Bossuyt A. Eur. J. Nucl. Med. 28 (2001) 133-135
29. Tu Z., Xu J., Jones L.A., Li S., Dumstorff C., Vangveravong S., Chen D.L., Wheeler K.T., Welch M.J., and Mach R.H. J. Med. Chem. 50 (2007) 3194-3204
30. Rowland D.J., Tu Z., Xu J., Ponde D., Mach R.H., and Welch M.J. J. Nucl. Med. 47 (2006) 1041-1048
31. Tu Z., Dence C.S., Ponde D.E., Jones L., Wheeler K.T., Welch M.J., and Mach R.H. Nucl Med. Biol. 32 (2005) 423-430
32. Friebe M., Mahmood A., Bolzati C., Drews A., Johannsen B., Eisenhut M., Kraemer M., Davison A., and Jones A.G. J. Med. Chem. 44 (2001) 3132-3140
33. Choi S.R., Yang B., Plo{combining double acute accent}ssl K., Chumpradit S., Wey S.P., Acton P.D., Wheeler K., Mach R.H., and Kung H.F. Nucl. Med. Biol. 28 (2001) 657-666
34. M.G. Mamolo, D. Zampieri, C. Zanette, C. Florio, S. Collina, M. Urbano, et al. Eur. J. Med. Chem., in press. doi:10.1016/j.ejmech.2007.09.012.
35. Ablordeppey S.Y., Fischer J.B., and Glennon R.A. Bioorg. Med. Chem. 8 (2000) 2105-2111
36. Ucar H., Cacciaguerra S., Spampinato S., Van deerpoorten K., Isa M., Kanyonyo M., and Poupaert J.H. Eur. J. Pharmacol. 335 (1997) 267-273
37. Lavesque S., St-Denis Y., Bachand B., Preville P., Leblond L., Winocur P.D., Edmunds J.J., Rubin J.R., and Siddiqui M.A. Bioorg. Med. Chem. Lett. 11 (2001) 3161-3164